ADAR1 Capital Management’s Lipocine LPCN Stock Holding History

ADAR1 Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,180	Closed	-$185K	–	318
2026 Q1	$185K	Buy	+23,180	New	+$202K	0.01%	264

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ADAR1 Capital Management's LPCN Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 23,180 shares — an estimated $185K sold.

ADAR1 Capital Management first reported a position in LPCN in Q1 2026 and held it in 1 quarter. The position peaked at $185K in Q1 2026. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

ADAR1 Capital Management reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 23,180 Lipocine shares in Q2 2026, an estimated $185K.
ADAR1 Capital Management first reported a position in Lipocine in Q1 2026 and held it in 1 quarter.
ADAR1 Capital Management's Lipocine position peaked at $185K in Q1 2026.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.